Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up

British Journal of Psychiatry

Volumn 207, Issue 4, 2015, Pages 357-362

  Tajika, Aran ^a   Ogawa, Yusuke ^a   Takeshima, Nozomi ^a   Hayasaka, Yu ^a   Furukawa, Toshi A ^a  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; FOLLOW UP; GENERAL PRACTICE; HUMAN; INTERVENTION STUDY; MEDICAL LITERATURE; PSYCHIATRIC TREATMENT; PSYCHIATRY; REPLICATION STUDY; RESEARCH; REVIEW; SAMPLE SIZE; STUDY DESIGN; BIBLIOMETRICS; PUBLICATION; STATISTICS AND NUMERICAL DATA;

BIBLIOMETRICS; PERIODICALS AS TOPIC; PSYCHIATRY; SAMPLE SIZE;

EID: 84943759227     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.143701     Document Type: Review

References (26)

1. US National Library of Medicine. Fact Sheet. MEDLINE, PubMed, and PMC (PubMed Central): How Are They Different? US National Library of Medicine, 2015 (http://www.nlm.nih.gov/pubs/factsheets/dif-med-pub.html).
2. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218-28.
3. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA 2012; 308: 1676-84.
4. Nieminen P, Rucker G, Miettunen J, Carpenter J, Schumacher M. Statistically significant papers in psychiatry were cited more often than others. J Clin Epidemiol 2007; 60: 939-46.
5. Hunt GE, Cleary M, Walter G. Psychiatry and the Hirsch h-index: the relationship between journal impact factors and accrued citations. Harv Rev Psychiatry 2010; 18: 207-19.
6. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004; 57: 1124-30.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
8. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
9. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2: e124.
10. Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: is there a rigid hierarchy? Circulation 2008; 118: 1675-84.
11. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000; 19: 3127-31.
12. Cohen J. Statistical Power Analysis in the Behavioral Sciences. Erlbaum, 1988.
13. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Cochrane Collaboration, 2011.
14. In t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
15. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7: 402-11.
16. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968-76.
17. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-26.
18. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebocontrolled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841-9.
19. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11: 673-86.
20. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry 2000; 176: 249-52.
21. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336: 601-5.
22. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012; 157: 429-38.
23. Cumming G. Replication and p intervals: p values predict the future only vaguely, but confidence intervals do much better. Perspect Psychol Sci 2008; 3: 286-300.
24. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008; 19: 640-8.
25. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106.
26. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.